Sugi Predict

Sugi Predict / Compounds / Hydroxyamine

Hydroxyamine

Hydroxyamine

SCHEMBL4553678

NO.O=C(O)c1cnc(N2CCN(S(=O)(=O)c3ccccc3-c3ccsc3CN3CCCC3)CC2)s1

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 13/20 0.46
▸ HDAC4 P56524 13/20 0.46
▸ HDAC1 Q13547 13/20 0.46
▸ HDAC7 Q8WUI4 13/20 0.46
▸ HDAC2 Q92769 13/20 0.46
▸ HDAC10 Q969S8 13/20 0.46
▸ HDAC11 Q96DB2 13/20 0.46
▸ HDAC8 Q9BY41 13/20 0.46
▸ HDAC6 Q9UBN7 13/20 0.46
▸ HDAC9 Q9UKV0 13/20 0.46
▸ HDAC5 Q9UQL6 13/20 0.46
▸ SCD O00767 2/20 0.40
▸ ALOX5AP P20292 1/20 0.36
▸ FEN1 P39748 1/20 0.36
▸ PKM P14618 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydroxyamine SCHEMBL4433819 0.81 HDAC3 (0.52) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL4292254 0.78 HDAC1 (0.61) HDAC3HDAC4HDAC1HDAC7HDAC2
Hydroxyamine SCHEMBL6415612 0.76 HDAC3 (0.50) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL5319421 0.72 HDAC3 (0.80) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL5318744 0.71 HDAC3 (0.57) HDAC3HDAC4HDAC1HDAC7HDAC2
Hydroxyamine SCHEMBL4186584 0.69 HDAC3 (0.52) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL28919033 0.68 HDAC3 (0.58) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL28919064 0.67 HDAC3 (0.57) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL4016791 0.67 KMT2A (0.56) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL5336978 0.67 HDAC3 (0.53) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050250784-A1 Inhibitors of histone deacetylase MIIKANA THERAPEUTICS CORPORATION 2005-11-10 — — US claimed
US-20050197336-A1 Inhibitors of histone deacetylase MIIKANA THERAPEUTICS CORPORATION 2005-09-08 — — US claimed
US-20090203010-A1 MSMB-gene based diagnosis, staging and prognosis of prostate cancer KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2009-08-13 — — US disclosed
US-20050250784-A1 Inhibitors of histone deacetylase MIIKANA THERAPEUTICS CORPORATION 2005-11-10 — — US disclosed
US-20050197336-A1 Inhibitors of histone deacetylase MIIKANA THERAPEUTICS CORPORATION 2005-09-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197336-A1 Inhibitors of histone deacetylase HDAC1, HDAC11, HDAC10 HDAC3 6/4885HDAC4 11/4885HDAC1 1/4885
US-20050250784-A1 Inhibitors of histone deacetylase HDAC1, HDAC11, HDAC10 HDAC3 6/4885HDAC4 11/4885HDAC1 1/4885
US-20090203010-A1 MSMB-gene based diagnosis, staging and prognosis of prostate cancer MAT2B, DNMT3B, SHBG HDAC3 3834/4885HDAC4 2788/4885HDAC1 3460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.